Investor Presentaiton

Investor presentation First three months of 2017 Continued global roll-out of SaxendaⓇ and an evolving obesity portfolio SaxendaⓇ value share of anti-obesity medications in selected countries Mexico Germany 80% 60% 40% 20% 0% 50 Australia Italy USA Brazil Canada Denmark Spain 77% 66% 44% 41% Slide 11 The global obesity potential The unmet need in obesity • Only 2% of the 600 million people with obesity are treated with an AOM SaxendaⓇ and obesity pipeline • . Successful uptake of SaxendaⓇ supports Novo Nordisk's long term commitment to obesity treatment SaxendaⓇ has been launched in 18 markets and represents 36% of the current patient growth for the AOM market Novo Nordisk obesity pipeline includes semaglutide for obesity in phase 2 development and six projects in phase 1 Key global initiatives Educate HCPs in obesity management Drive patient engagement via SaxendaⓇ care • Drive recognition of obesity as a chronic disease · Improve market access to obesity care 23% 21% 18% 10% 6% · 10 15 20 25 • Months from launch Source: IMS, February 2017 for all countries (except for Denmark where the last data point is July 2016). Note: AOM market size varies significantly between countries changing diabetes Source: WHO, IDF and IMS MIDAS (MAT Q3 2016) AOM: Anti-obesity medication HCPS: Health care professionals

View entire presentation